Humacyte (NASDAQ:HUMA) Earns “Buy” Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a report released on Thursday morning,Benzinga reports. D. Boral Capital currently has a $25.00 target price on the stock.

A number of other equities research analysts have also recently commented on HUMA. TD Cowen reissued a “buy” rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. Piper Sandler set a $6.00 price objective on Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price target on shares of Humacyte in a research note on Friday, September 20th. Finally, BTIG Research restated a “buy” rating and set a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Humacyte currently has a consensus rating of “Buy” and a consensus target price of $13.00.

Humacyte Price Performance

Shares of HUMA stock opened at $4.49 on Thursday. The stock’s 50-day moving average is $5.31 and its 200 day moving average is $6.19. Humacyte has a 1-year low of $2.43 and a 1-year high of $9.97. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. The company has a market cap of $565.11 million, a P/E ratio of -3.35 and a beta of 1.47.

Insider Buying and Selling at Humacyte

In other Humacyte news, Director Kathleen Sebelius sold 5,182 shares of Humacyte stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total transaction of $27,982.80. Following the completion of the transaction, the director now owns 40,276 shares in the company, valued at approximately $217,490.40. This trade represents a 11.40 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the transaction, the director now directly owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,584,153 shares of company stock worth $13,476,796. Company insiders own 11.20% of the company’s stock.

Institutional Investors Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently made changes to their positions in HUMA. State Street Corp lifted its stake in shares of Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after purchasing an additional 1,895,529 shares during the period. Vanguard Group Inc. increased its stake in shares of Humacyte by 28.7% in the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after purchasing an additional 896,415 shares in the last quarter. Geode Capital Management LLC raised its holdings in Humacyte by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,040,218 shares of the company’s stock worth $11,101,000 after purchasing an additional 179,120 shares during the period. Millennium Management LLC boosted its position in Humacyte by 504.3% during the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after purchasing an additional 1,334,641 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Humacyte by 10.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 721,318 shares of the company’s stock worth $3,924,000 after purchasing an additional 66,946 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.